Navigation Links
ShangPharma Announces Opening of New Facility to Support Lilly's Pipeline
Date:1/10/2012

SHANGHAI, Jan. 10, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it has opened a new facility to meet the growing capacity needs of one of its largest customers, Eli Lilly and Company ("Lilly"). ShangPharma also announced that it has signed a multi-year extension of its contract with Lilly.

"We are delighted to extend and deepen our highly productive relationship with Lilly," said Michael Xin Hui, founder and Chief Executive Officer of ShangPharma. "Renewing our agreement to serve as a key support partner for Lilly's discovery services is a clear indication that international pharmaceutical companies appreciate the high quality of ShangPharma's team and the excellence of our R&D capability. Our focus on building trust with companies through years of cooperation helps ShangPharma better understand our customers' needs and exceed their expectations."

ShangPharma's newly opened facility adds 110,000 square feet of laboratory and office space to the Company's overall capacity, and is fully dedicated to supporting Lilly's ongoing and future projects. The opening of the facility coincides with the multi-year extension of ShangPharma's contract with Lilly.

William Dai, ShangPharma's Chief Financial Officer, commented, "The opening of this state of the art facility gives us the capacity to expand our operations and better meet Lilly's growing demand.  We expect to achieve high utilization of the new facility from day one."

About ShangPharma

ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

Safe Harbor: Forward-Looking Statements

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "likely to" or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. The quotations from management in this press release contain forward-looking statements. The Company may also make written or oral forward-looking statements in its reports filed or furnished with the U.S. Securities and Exchange Commission, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements and are subject to change, and such change may be material and may have a material adverse effect on the Company's financial condition and results of operations for one or more periods. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained, either expressly or impliedly, in any of the forward-looking statements in this press release. The Company expects to face potential risks and uncertainties related to its ability to, among other things, attract, train, motivate and retain skilled scientists; diversify its customer base and adapt to potential loss of sales to, or significant reduction in orders from, any of its major customers; adapt its business to industry trends, such as fluctuations in the R&D budgets of pharmaceutical and biotechnology industry participants; protect the intellectual property rights of its customers; comply with applicable regulations and industry standards; compete effectively in its industry, which may subject it to increasing pricing pressure and reduce the demand for its services; expand and market its services and manage its growth; and develop and maintain effective internal control over financial reporting; as well as other risks outlined in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any such information, except as required under applicable law.

For further information, please contact:  

ShangPharma
Ms. Lan Xie
VP of Finance and Investor Relations
Email: ir@shangpharma.com

Brunswick Group
Josh Gartner
Email: shangpharma@brunswickgroup.com
Phone: 86-10-5960-8600


'/>"/>
SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ShangPharma Announces Appointment of Benson Tsang as a Member of the Board of Directors and Audit Committee
2. ShangPharma to Present at the Citibank Global Health Care Conference from March 1 - 3, 2011
3. ShangPharma Announces Fourth Quarter and Fiscal Year 2010 Results
4. ShangPharma Corporation Files 2010 Annual Report on Form 20-F
5. ShangPharma Corporation to Announce First Quarter 2011 Financial Results on May 19, 2011
6. ShangPharmas Biologics Division Announces Accelerated Achievement of Milestones for Two Multi-Stage Projects
7. ShangPharma Announces Up to $10 Million Share Repurchase Program
8. ShangPharma Corporation to Hold 2011 Annual General Meeting on October 14, 2011
9. ShangPharma Corporation Announces Resignation of a Director
10. ShangPharma Corporation Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
11. ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016 The new report "Global Blood Monitoring & Cardiac Monitoring Devices ... Consulting group reveals that global market for blood monitoring & cardiac ... expected to grow to US$ 24,830.1 million by 2019 at a ... America , Europe , Asia-Pacific ... and Africa . The three major ...
(Date:2/9/2016)... , Feb. 9, 2016  Johnson & Johnson ... Capital Markets Global Healthcare Conference on Tuesday, Feb. 23, ... Dominic Caruso , Vice President, Finance & Chief ... Consumer will represent the Company in a session scheduled ... . --> www.investor.jnj.com . --> ...
(Date:2/9/2016)... , Feb. 9, 2016  Bluestar Silicones will ... product line for long-term implant applications and announce ... Design & Manufacturing (MD&M) West Conference (Booth #1759), ... --> --> Available ... Biomedical LSRs offer outstanding physical properties enabling our ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus ... the continuation of the ‘Pay It Forward’ program into 2016. BioPlus partners with ... our specialty pharmacy. , “Since our Pay It Forward program began, we ...
(Date:2/9/2016)... ... 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: BONT), ... announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, Froedtert ... the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic Cancer ...
(Date:2/9/2016)... ... February 09, 2016 , ... IsoComforter, Inc., one of ... the newly designed, innovative shoulder wrap. The newly designed shoulder wrap has ... injured arm and shoulder to promote faster healing. It is highly recommended for ...
(Date:2/9/2016)... ... , ... i2i Systems, an early innovator and developer of population health management ... KLAS report, Population Health Management 2015: How Far Can Your Vendor Take You? ... (PHM). The latest KLAS Report, leveraging over 200 user interviews, shines a light ...
Breaking Medicine News(10 mins):